Quick Answer
Altimmune, Inc. reported Research And Development Expense of $66.43 million for the year ending 2025.
- Altimmune, Inc. showed a decrease of -19.2% in Research And Development Expense from 2024 to 2025.
- This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $5.94 million | Q3 2010: $6.17 million | Q1 2011: $5.82 million | Q2 2011: $5.98 million | Q3 2011: $4.88 million | Q1 2012: $4.71 million | Q2 2012: $4.92 million | Q3 2012: $5.14 million | Q1 2013: $5.23 million | Q2 2013: $3.40 million | Q3 2013: $2.56 million | Q1 2014: $3.43 million | Q2 2014: $2.37 million | Q3 2014: $1.73 million | Q1 2015: $1.61 million | Q2 2015: $1.22 million | Q3 2015: $1.13 million | Q1 2016: $1.03 million | Q2 2016: $1.38 million | Q3 2016: $2.40 million | Q1 2017: $2.79 million | Q2 2017: $5.25 million | Q3 2017: $5.91 million | Q1 2018: $5.75 million | Q2 2018: $4.92 million | Q3 2018: $4.73 million | Q1 2019: $3.22 million | Q2 2019: $2.95 million | Q3 2019: $8.73 million | Q1 2020: $7.19 million | Q2 2020: $16.59 million | Q3 2020: $17.04 million | Q1 2021: $11.88 million | Q2 2021: $13.27 million | Q3 2021: $29.21 million | Q1 2022: $15.10 million | Q2 2022: $15.99 million | Q3 2022: $20.26 million | Q1 2023: $17.25 million | Q2 2023: $13.25 million | Q3 2023: $18.39 million | Q1 2024: $21.49 million | Q2 2024: $21.16 million | Q3 2024: $19.80 million | Q1 2025: $15.83 million | Q2 2025: $17.24 million | Q3 2025: $14.96 million.
- Over the full 16 years of available data (2010 to 2025), Altimmune, Inc.'s Research And Development Expense has grown by 218.2%.
- Historical annual values: Fiscal year 2025: $66.43 million | Fiscal year 2024: $82.23 million | Fiscal year 2023: $65.80 million | Fiscal year 2022: $70.54 million | Fiscal year 2021: $74.54 million | Fiscal year 2020: $49.77 million | Fiscal year 2019: $17.77 million | Fiscal year 2018: $18.46 million | Fiscal year 2017: $18.41 million | Fiscal year 2016: $7.22 million | Fiscal year 2015: $5.13 million | Fiscal year 2014: $9.32 million | Fiscal year 2013: $15.29 million | Fiscal year 2012: $19.51 million | Fiscal year 2011: $21.22 million | Fiscal year 2010: $20.88 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: